## DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION 250 Marguette Ave, Ste. 600 8/27/2018-8/31/2018 Minneapolis, MN 55401 3008927138 (612)334-4100 Fax: (612)334-4134 NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Stephen C. Morton, CEO FIRM NAME STREET ADDRESS Morton Drug Company dba Morton LTC 201 E Bell St CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED Neenah, WI 54956-5096 Producer of Sterile and Non-Sterile This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: OBSERVATION 1 You produced beta-lactam drugs without providing adequate cleaning of work surfaces to prevent crosscontamination. Specifically, you aseptically processed beta-lactam antibiotics in the ISO 5 (b) (4) in the past three months. Your cleaning procedure does not identify the use of appropriate cleaning agents to reduce the risk of crosscontamination for these products. OBSERVATION 2 Materials or supplies were not disinfected prior to entering the aseptic processing areas. Specifically, on August 27, 2018, we observed the operator wipe supplies in the ISO 8 area with and continue to transfer them into the ISO 5 aseptic processing area with no additional wipe down or the supplies. These supplies were used in the aseptic processing of daptomycin 425 mg in 100 mL of 0.9% NaCl, prescription

(b) (6)

## OBSERVATION 3

FORM FDA 483 (09/08)

PREVIOUS EDITION ORSOLETE

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.


Specifically, your firm's practice of media fills does not include using a microbiological growth medium in place of the product. Your firm injects (b) (4)

EMPLOYEE(S) SIGNATURE	C C	DATE ISSUED
Sandra A Hughes, Tenzin Jangchup,	Sentine A Hughes Service Or Senter A Hughes & Disse Service 06-31-2018 10:56:00	8/31/2018
		144

INSPECTIONAL OBSERVATIONS

PAGE 1 of 2 PAGES

## DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION 8/27/2018-8/31/2018 FEI NUMBER 250 Marquette Ave, Ste. 600 Minneapolis, MN 55401 3008927138 (612)334-4100 Fax: (612)334-4134 NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Stephen C. Morton, CEO FIRM NAME STREET ADDRESS Morton Drug Company dba Morton LTC 201 E Bell St TYPE ESTABLISHMENT INSPECTED CITY, STATE, ZIP CODE, COUNTRY Neenah, WI 54956-5096 Producer of Sterile and Non-Sterile Products



SEE REVERSE
OF THIS PAGE

EMPLOYEE(S) SIGNATURE

Sandra A Hughes, Investigator Tenzin Jangchup, Investigator

DATE ISSUED 8/31/2018

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

INSPECTIONAL OBSERVATIONS

PAGE 2 of 2 PAGES